Global Cord Blood Corporation (CO)
| Market Cap | 400.08M |
| Revenue (ttm) | 194.26M |
| Net Income (ttm) | 78.29M |
| Shares Out | 133.92M |
| EPS (ttm) | 0.64 |
| PE Ratio | 5.06 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7 |
| Open | 2.21 |
| Previous Close | 2.99 |
| Day's Range | 2.99 - 2.99 |
| 52-Week Range | 2.03 - 5.50 |
| Beta | -0.05 |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | Feb 27, 2023 |
About CO
Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2022, it operated three cord blood banks, including one in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province. The company was formerly ... [Read more]
Financial Performance
In 2022, CO's revenue was 1.24 billion, an increase of 7.21% compared to the previous year's 1.16 billion. Earnings were 501.07 million, a decrease of -1.41%.
Financial numbers in CNY Financial StatementsNews
Global Cord Blood Corporation Announces Appointment of Joint Provisional Liquidators by The Grand Court Of The Cayman Islands
HONG KONG--(BUSINESS WIRE)--Global Cord Blood Corporation (NYSE: CO) (“GCBC” or the “Company”), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processin...
The Grand Court of the Cayman Islands Granted Blue Ocean's Application to Appoint Joint Provisional Liquidators for Global Cord Blood Corporation
NEW YORK--(BUSINESS WIRE)--Blue Ocean Structure Investment Company Ltd., (“Blue Ocean”) a significant shareholder of Global Cord Blood Corporation (the “Company” or “Global Cord”) (NYSE: CO), today an...
Global Cord Blood Corporation Files Annual Report on Form 20-F
HONG KONG , Aug. 16, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem ...
Global Cord Blood Corporation Obtained Injunction Order Against Blue Ocean in respect of Purported EGM
HONG KONG , July 6, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO, "GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem ce...
Global Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2022
Added 16,423 New Subscribers in 4QFY22 4QFY22 Revenues Down 1.7% YoY to RMB297.2 Million ($46.9 Million) 4QFY22 Gross Profit Down 0.5% YoY to RMB255.2 Million ($40.3 Million) 4QFY22 Operating Income D...
Global Cord Blood Corporation Announced Cellenkos Receives FDA Clearance of IND Application for CK0804 as Add on Therapy to Ruxolitinib for the Treatment of Myelofibrosis
HONG KONG , June 16, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem ...
Shareholders Led by Blue Ocean Announce Successful Results of Extraordinary General Meeting of Global Cord Blood Corporation
NEW YORK--(BUSINESS WIRE)--Blue Ocean Structure Investment Company Ltd., (“Blue Ocean”) and shareholders representing over 75% of the outstanding shares of Global Cord Blood Corporation (the “Company”...
Global Cord Blood Corporation Announces Purported EGM Is Not Validly Convened
HONG KONG , June 16, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO, "GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem c...
Shareholders Led by Blue Ocean Call Extraordinary General Meeting of Global Cord Blood Corporation Shareholders to Terminate its Proposed Acquisition of Cellenkos, Inc. and Elect New Board
NEW YORK--(BUSINESS WIRE)--Blue Ocean Structure Investment Company Ltd.,(“Blue Ocean”) announced today that shareholders representing no less than 75% of the outstanding shares of Global Cord Blood Co...
Blue Ocean Announces Virgin Islands Court Grants Injunction Order Prohibiting Golden Meditech from Taking Any Steps on a Purported Share Charge from Blue Ocean or Pursuing the Removal of Blue Ocean's Representative as a Director of Global Cord Blood
NEW YORK--(BUSINESS WIRE)--Blue Ocean Structure Investment Company Ltd. (“Blue Ocean”), a significant shareholder of Global Cord Blood Corporation (the “Company” or “Global Cord”) (NYSE: CO), today an...
Blue Ocean Comments on Fraudulent Claims from Conflicted Party Golden Meditech Regarding Global Cord Blood Corporation
NEW YORK--(BUSINESS WIRE)--Blue Ocean Structure Investment Company Ltd. (“Blue Ocean”), a significant shareholder of Global Cord Blood Corporation (the “Company” or “Global Cord”) (NYSE: CO), today co...
Global Cord Blood Corporation Announces Receipt of Blue Ocean Petition
HONG KONG , May 10, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO, "GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem ce...
3 Hot Penny Stocks to Buy in Q1 for Huge Potential
3 penny stocks to consider buying as they are undervalued, have low levels of debt and strong anticipated EPS growth. The post 3 Hot Penny Stocks to Buy in Q1 for Huge Potential appeared first on Inve...
Global Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2022
Added 18,985 New Subscribers in 3Q22 Revenues Up 9.1% YoY to RMB317.2 Million ($49.8 Million) Gross Profit Up 9.8% YoY to RMB269.9 Million ($42.4 Million) Operating Income Up 20.8% YoY to RMB1...
Global Cord Blood Corporation to Report Third Quarter and First Nine Months Fiscal 2022 Financial Results
HONG KONG, Feb. 23, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) (the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell proces...
Global Cord Blood Corporation Announces Rejection of Alternate Ocean Proposal
HONG KONG, Dec. 16, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem c...
Global Cord Blood Corporation Announces Results of 2021 Annual General Meeting
HONG KONG, Dec. 7, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem ce...
Global Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2022
Added 19,066 New Subscribers in 2Q22 Revenues Up 9.8% YoY to RMB313.7 Million ($48.7 Million) Gross Profit Up 11.0% YoY to RMB267.5 Million ($41.5 Million) Operating Income Up 15.3% YoY to RMB...
Global Cord Blood Corporation to Report Second Quarter and First Half Fiscal 2022 Financial Results
HONG KONG, Nov. 17, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) (the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell proces...
Global Cord Blood Corporation to Hold Annual General Meeting in Hong Kong on December 7, 2021
HONG KONG , Sept. 17, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem...
Global Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2022
1Q22 Added 19,673 New Subscribers Revenues Up 12.2% YoY to RMB315.2 Million ($48.8 Million) Gross Profit Up 12.6% YoY to RMB267.3 Million ($41.4 Million) Operating Income Up 17.3% YoY to RMB156.6 Mill...
Global Cord Blood Corporation to Report First Quarter Fiscal 2022 Financial Results
HONG KONG, Aug. 25, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) (the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell proces...
Global Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2021
Added 19,367 New Subscribers in 4Q21 Revenues Up 0.8% YoY to RMB302.3 million ($46.1 million) Net Income Attributable Up 31.7% YoY to RMB127.7 million ($19.5 million) Operating Cash Flow Up 134.6% YoY...
Global Cord Blood Corporation to Report Fourth Quarter and Full Year Fiscal 2021 Financial Results
HONG KONG, June 22, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) (the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell proces...
Global Cord Blood Corporation Announces Formation of a Special Committee to Evaluate Non-Binding Proposal
HONG KONG, March 15, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem ...